Archive: Company News
Company News: Curetis Group Company Ares Genetics is Granted Key European Patent on Genetic Resistance Testing
— Patent broadly covers genetic biomarkers and biomarker combinations indicating antibiotic resistance
— First of eleven similar patents filed covering various pathogen/drug combinations
— Strengthens unique position of ARESdb, Ares Genetics’ knowledgebase of antimicrobial resistance genetics
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that its wholly owned subsidiary Ares Genetics GmbH has received a notification by the European Patent Office (EPO) on the decision to grant the European Patent No. 3 099 813 titled “Genetic Resistance Testing”. Read more…
Company News: Curetis To Attend Key Conferences in the Third Quarter of 2019
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that the Company will be attending several key conferences in the third quarter of 2019.
Company News: Curetis Reports Results of the Annual General Meeting Held on June 27, 2019
– All proposed AGM resolutions approved by shareholders
Company News: VesselSens: First Research Group at Life Science Inkubator Bonn to Receive Funding from EXIST Program
— Preclinical development of an implantable sensor system for the wireless detection of vascular constriction funded with EUR 1 mn
VesselSens is the first research group based at Life Science Inkubator (LSI) Bonn, Germany, to receive funding from the EXIST Transfer of Research Program by Germany’s Federal Ministry of Economic Affairs and Energy (BMWi). VesselSens is developing novel sensor technologies for the early, non-invasive detection of a recurrent vascular constriction at the site of an implanted stent (restenosis). Read more…